Table 4.
Clinical outcomes by treatment group
| PMX-HP group | Non PMX-HP group | P valuea | |
|---|---|---|---|
| Overall | n = 29 | n = 30 | |
| Mortality on day 3, n (%) | 3 (10.3) | 10 (33.3) | 0.058 |
| Mortality on day 7, n (%) | 6 (20.7) | 12 (40.0) | 0.11 |
| Mortality on day 28, n (%) | 17 (58.6) | 15 (50.0) | 0.51 |
| MAKE 28b (%) | 22 (75.9) | 22 (73.3) | 1.00 |
| Alive on day 28 | n=13c | n = 15 | |
| ICU-free days (Q1, Q3) | 0 (0, 10) | 0 (0, 8) | 0.99 |
| Ventilator-free days (Q1, Q3) | 0 (0, 8) | 0 (0, 0) | 0.28 |
| RRT, n (%) | 7 (53.8) | 6d (50.0) | 0.85 |
| Serum creatinine (mg/dl) (Q1, Q3) | 1.4 (1.1, 2.2) | 2.1 (1.3, 2.5) | 0.59 |
| Vasopressor free days (Q1, Q3) | 0 (0, 25) | 11.5 (0, 25) | 0.47 |
| AKI at baseline | n = 25 | n = 25 | |
| Renal recoverye, n (%) | 5 (20.0) | 3 (12.0) | 0.70 |
Data represent median (25th percentile, 75th percentile) unless otherwise noted
Data measured on day 28 unless otherwise noted
PMX-HP polymyxin B hemoperfusion, ICU intensive care unit, Q1 25th percentile, Q3 75th percentile, RRT renal replacement therapy, AKI acute kidney injury
aFisher’s exact test for categorical variables; Kruskal–Wallis test for continuous variables
bMajor adverse kidney events on day 28, comprised of death, or dialysis dependence, or persistent AKI on day 28
cIn the PMX-HP group one patient died by the end of day 28, but his values were measured and used in the analysis
dIn the non-PMX-HP group, RRT data were available in 12 patients
eRenal recovery mean alive, dialysis independence and no AKI on day 28 after enrollment